What question did this study set out to answer?

Investigate the efficacy and immune modulation of STK-012 when combined with pembrolizumab and chemotherapy in PD-L1 negative non-squamous NSCLC.

Selective Immune Activation of Antigen Activated T Cells with STK-012 in Non-Squamous NSCLC

View Full Paper

Ask AI

Bookmark

Investigate the efficacy and immune modulation of STK-012 when combined with pembrolizumab and chemotherapy in PD-L1 negative non-squamous NSCLC.
Conducted a phase 1a/b study with STK-012 administered subcutaneously every 3 weeks alongside standard chemotherapy and pembrolizumab.
Analyzed blood samples for cytokine levels using chemoluminescence assays.
Assessed T cell proliferation and activation through spectral flow cytometry and TCR sequencing.
Achieved an objective response rate of 55% across efficacy-evaluable patients, with notable responses in specific mutations and histologies.
Induced significant proliferation of CD8+ and CD4+ T cells, with notable increases in previously exhausted T cells.
Sustained elevation of cytokines like IFNγ and IL-18 was observed, indicating robust T cell activation.

No takes yet. Share an insight, caveat, or question.

Phase 1a/b trial shows enhanced T cell activation and proliferation in PD-L1 negative non-squamous NSCLC, suggesting promising efficacy.

Punekar et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark